and And today's our second an joining good Jennifer. followed We everyone. quarter us XXXX you, financial call. appreciate a summary. with for start financial results more detailed you update, overview Thank We'll by of afternoon, corporate a
are the an and Finance, and respective or Whitaker, on our for narsoplimab biologics thrombotic call with me specifically Clinical. Joining start TA-TMA. quarter first Jacobsen, and the the today Melfi, Cathy MASP-X Nadia program Steve post-action we on microangiopathy review Type our Regulatory, this We'll of transplant-associated Dac, year, heads Mike FDA division in Commercial, In update of had application, meeting or license a stem BLA. cell A our with
the process higher Drugs, our is our resolution receipt level to of dispute division legal and regulatory which advisors decision deciding Office with a we or meeting, of resolution. OND. made authority, in to appeal consultation The a the Following formal the in the official that sponsor minutes a New case decided at pursue dispute to of allows
our in comprised June. briefing use all regulatory of be was dispute literature in FDA precedent, history, a believe for OND narsoplimab on that and the a as previously request we across resolution originally The our BLA submitted filed. clinical TA-TMA approved components, regulatory case based to presents As data, that detailed compelling to document reported, should request
the we meeting, shareholders additional the FDA BLA, as briefing of well leading were The no will month. investor part by dispute indication for briefing and resolution, with FDA meeting submission exception. provide decided, in our met cell does last not familiar any experts Once OND transplantation. and was how our stem a community. that at the that At of publicly unless time with month. share dispute typically of decision rendered We Following package. with awaiting and official joined be decision currently package meeting several should OND prepared our standard our procedures this FDA it the received, with which requires was We're determines resolution and be we'll deciding
treatment for Let's the IgA nephropathy. turn now of to narsoplimab
are by X-month those data available. data We and continue X and scheduled ARTEMIS-IGAN trial mid our to the We Phase publicly year. forward to look proteinuria read next out enrollment advance to making
programs. We're as Our Postacute resource we've X a also narsoplimab AHUS our below therapeutic both other hemolytic narsoplimab potential for also infection, allocation or uremic reported as a as evaluating on-going is those COVID, previously severe complement also long syndrome. its result COVID-XX and Phase trial is atypical and prioritization Sequelae it's but of known for in acute SARS-CoV-X PASC. as or
benefit therapies multiple no in by continues sponsored better which To show effective trials over part I-SPY the for to as publicly reported trial evaluated the was and agent continue current SARS-CoV-X date, platform COVID-XX. has potential less Collaborative, of variants I-SPY agents the arguably proving new hoped Healthcare COVID-XX are has Leap remains a Quantum standard-of-care. and now been to than COVID-XX As to Narsoplimab therapeutics grow. the and for emerge antivirals vaccines need of
disclosure to narsoplimab to forward continue of the results. look Quantum’s We
Seattle, pathway in research COVID at groups teams lectin and complement the manuscripts in University et of Ali the recently Immunology and in Lynch Clinical of of from work is the increasingly in by PASC to specifically Omeros central both discoveries et Frontiers related severe Medicine. pathophysiological Cambridge The in The focus al. mechanism this these added of leading role the by acute describe important internationally. and in to al. effort, the and U.K. the publications breaking Together, publishing COVID-XX. ground Translational our role of and publications
lectin in patients lectin pathway this activation. activation It's show consumption, to that early marked COVID-XX leads severe by which of of is and that morbidity hyper disease, a of risk with clinically infection. complement is in The and severe pathway loss mediated are the Specifically, result driven of hyper against to which COVID-XX. death protection infections, increased known be hypocomplementemia, complement cause secondary common
are with that mortality consumptive that risk to becoming implication is of acute driver at government all meaning The in and low with of ill. would clear marker share reduce showed patients hospitals a patients elevated assay treatment severely for of on So effectively, and MASP-X for activity, a complement hyper the very samples independent. complement multiplex overall patients pathway Well antibody function that commercially CHXX profile these developing ICU Anaphylatoxins inhibits high these funded narsoplimab the complement now identified severe then CXa, consumption data of narsoplimab multiple the a lectin residual COVID-XX lectin complement benefit functional where in? admission, complex, levels consumption by the secondary from a fit and U.K. A patients does over as acute COVID-XX acute, is of measure key COVID-XX. tool admission functional Based ICU morbidity and is physicians longitudinal serum At from inhibitor these activation risk this soon as had antibody seen. levels elevated of available we’re at subset COVID-XX activity, thereby complement throughput which bactericidal Collectively, infection. and CXa. preventing patients CX consortia. from narsoplimab identifying evaluated restores XXX of and data, low levels these We've severe is levels indicate platform as pathway and COVID-XX of activation activity, biomarker
two program Narsoplimab acting as and generation this of molecules MASP-X discuss second long has trials. week, which now more MASP-X are OMSXXXX antibody. clinical broadly Let's in our
clinical two We're which longer be add working been These also expected should an lectin possible. The a would as now as soon indications for OMSXXXX monthly Phase will to be is particular our to OMSXXXX once good pursue be and designed driven dosed once complimentary to Dosing trial subjects delivered our for MASP-X inhibitor our to molecule making or OMSXXXX. in MASP-X we're have to advantage. pathway small dosing oral to X evaluating narsoplimab first on intravenously enable progress us quarterly, orally administered duration be inhibitors. portfolio to subcutaneously
level our overview financial turn to results quarter. let's a the OMIDRIA for Now, high of and
reclassify previously Rayner Omeros The As to required reduction Surgical. earned December, contract to us revenue Rayner as transaction the strategic OMIDRIA from historical last our and and the sheet. divestiture completed the on record royalty of discussed to operations a expenses a as with OMIDRIA OMIDRIA commercial its drug all royalties balance ophthalmic discontinued asset
royalty of more which for currently XX%, OMIDRIA operating XX% the is Our sales of U.S. profit. than equates to rate net
of new quarter net of sales quarter, reported over the OMIDRIA OMIDRIA $XX.X and quarterly a all-time OMIDRIA first second $XX.X revenues represents high net Rayner of for million our a previous Rayner’s XXXX. the high. million, for of XX% This eclipses For sales increase
sales $XX.X quarter for on XX% Rayner the Our royalty was net million.
in required compared and prior of were for the year expenses, the to $XX.X Given zero, continuing and million reclassification OMIDRIA quarter revenues the net loss $XX.X reported our million, from revenues second as was quarter. our operations
to Our million overall $XX.X share $XX.X for compared million, in or was share, year. $X.XX per loss the quarter current last second $X.XX the per of quarter or
and were per share quarter. million or current for $X.XX or million share Our non-cash for the prior expenses $X.XX the $X.X per $X.X quarter year
June support investments hand of in we $XXX.X had As million cash XXXX, on-going to operations. XX available on and
and cash So $XX.X the second quarter in total, of of of to quarter I'm end decrease second the the -- is of our a investments million. first from change the sorry the in
for In royalties $XX.X have May of by XX we million primarily received Rayner be to OMIDRIA days sales June. earned. and paid additional Omeros to are within by being receivables an for Omeros of representing monthly addition, OMIDRIA royalties
which million We sales also agreement, not have have $XXX at used. we market the
continue minimal in expect to we we transition and the a to teams operations this ensure of product, quarter-over-quarter well smooth to it OMIDRIA disruption with closely to growth with customers. encouraged quarter, We're and the gone the During Rayner complete The all the work quarter. has transition by sales.
Congressional HOPD. of comment Outpatient qualifies when be for continuous NOPAIN the expect four Under non-opioid for of further the reconfirming numbering used between approximately and by group separate milestone right The momentum will given to management support and Act and These the Act also NOPAIN access rule million Senators proposed We're the congressional to eligible month in next. XX in the of exclusion Payment secured cataract by and the pain Republicans. providing a continue chambers. HOPDs as thing for in deserve We patients becoming performed for split in Democrats proposed before We non-opioid cataract roughly payment is diverse undergo regardless also in We of we the and non-opioids an XX% setting the solicited committees, OMIDRIA the Prospective the the advance for of their coalition bipartisan payment for management medical governing and rule, an the a of is CMSs separate they potentially issued for and the addiction charge OMIDRIA Systems country The ASC choices of CMS surgical has for physicians. are whether provide and of part separately advocacy the hospital expansion under HOPD an Act bill ASC XXXX the pleased patients like and passage surgical patient impressive the assembled now non-opioid and has and centers, to OMIDRIA bicameral period least ASCs. in Medicare departments pay pain positive strong legislation. Nation the expanding of this appreciate Omeros prevents OMIDRIA groups, or of outpatient caucuses. or likelihood exclusion good surgery receive that settings. on that societies relevant in NOPAIN XXX drugs the law a in include or Act the based separate and of be or terms this support major in CMS support public drugs $XXX access Omeros. The last the XXXX ambulatory years. transaction, the to Leading recovery and should in broad Rayner the voices boosted a and this patients prevention to as representing commitment Congress Act, Passing at HOPDs. of that equally for beyond procedures surgery has the milestone support trigger co-sponsors bipartisan Representatives that both would early across expect country and in payment House organizations would sponsors NOPAIN both NOPAIN ASC the with key to payment for and continues members and Representatives non-opioid or bills, Senate, chairpersons, in OMIDRIA
Looking cash costs at meaningful significantly complement MASP-X with sales of royalties stream that programs the of franchise continue our the the OMIDRIA, MASP-X, us our both the expect including we defray drug inhibitors. pipeline revenue for and to The non-dilutive in trajectory and flow long will OMIDRIA term. from near developing to helps provide
intellectual the dominant systems pathway. we a have MASP-X, for complement activator we around the position Just continue done as alternative property build key MASP-X, of to
MASP-X seven Let's a Nocturnal OMSXXX presenting meeting trial on evaluating healthy to Bern Having Complimented Paroxysmal market unsatisfactory preclinical an credits The a later successfully our this inhibitor. within Switzerland of from our administrative submitted community. is response our orphan OMSXXX preparing OMSXXX which the with and on lead tax, orphan now scientific have of for ravulizumab. OMSXXX on exclusivity includes certain late Hemoglobinuria clinical designation results Congress of FDA to growing enrollment trials, and trial for in treatment initiate X grants, of data in CX at X approval later program the We'll OMSXXX Human In benefits completed we're of who presentation PNH, study been drug marketing U.S. or Awareness turn July, year. drug in the Phase the to inhibitor at in a subjects, received Phase the have waiver patients fees. PNH. this of month European major Disease following be eligibility for years
dosing decreased or to We monthly a hold infrequently profile include expect disorders. advantages OMSXXX with over infection as that alternative agents expected are once for pathway could significant These administration other advantages once in and approved convenient risk related to quarterly. development as
might the targets phase increases the appear does in phase in no flu. and that pathway, mitigating on dosing background And disease. alternative or as in dosing common That of result acute is breakthrough in effect is acute on circulating other phase response not of inflammation the reactant. be to acute no concentration breakthrough. resulting phase a MASP-X drug longer not OMSXXX, simple acute in as be the be to reactant inflammation of has targeting body. unlike an the an Importantly, an reactant reactant greatly Because effective, concentration, its inflammation that can And disease risk MASP-X
quickly with expected efficacy obtaining these advantages, as Given OMSXXX data as possible. we're focused on
and pathway commercial If we trials understood ravulizumab, in advantages XXXX. patients, include PNH, they be inhibition proved alternative as we're data of evaluating accurate, patients described, in in should OMSXXX, in as biological agents is the our in efficacy of the around have early good safety Xb and that treatment, this and an PNH compelling. as program like to pathway. is and of unsatisfactory importance just like and naive expect OMSXXX well successfully OMSXXX be by the viability had So demonstrate I these we alternative addition to will. which Phase inhibiting on OMSXXX related one The created to diseases alternative indications. response expanding of glomerulopathy initiating OMSXXX or pathway who value demonstrate making to efficacy study PNH are targeting The in OMSXXX patients, well We're more CXG, and headway diseases CX of or our that dosing
or continue OMSXXX OMSXXX discussions disorders. Although addictive on-going inhibitor complement phosphodiesterase, we continue of PDEX programs clinical to to development prioritize those funding our our are access program third over to of for party
induced predictive models work develop of More patients prolonged our potential Emory L-DOPA primate researchers the following dyskinesias are our to to L-DOPA evaluating dyskinesias. addition University clinically, PDEX than inhibitors XX% In of addiction, at in in improve treatment. Parkinson's
the the Our viable indication immuno-oncology seeing we and OMSXXX. update commercial early expect existing opportunity patents final cover that broadly positive, have would I'll dyskinesia to we If our in today another programs year. data and close for this forward large we which we're look next with a cell killing that optimize conditioning evaluating of and sustained number focused cancers. immune-oncology developing checkpoints. both We're novel different target To to approach, yield a response. molecules been surface treat a intracellular cell on to date, primarily tumor anti more inhibitors taking has potent T tumor
to protection. combination Our tumors, liquid engineered targets to novel or solid of response for and believe We the GPRXXX, our T that of technology involves inhibitors has impact continuing a patients adenosine receptors these of more our quarter technology rates broad the the improve call for negative on native therapies. that, function. patent With and and Accounting to of of approach to limit car our Jacobson, we're detailed Across cell building pathways for potential certain T explore cell application cell other therapies Chief either landscapes hand receiving T results, cell therapies, Mike Officer to therapeutics over the this of a improve description both second financial and Mike? adoptive T we're human I'll
